Indian Journal of Cancer

SoMex Research and Health Organisation assessed the data collection in Immunotherapy in Lung Cancer at BMCHRC.

6 MAJOR ASCO UPDATE HIGHLIGHTS

OVERALL SURVIVAL DATE of PALBOCICLIB presented (TRIO-18) in first line setting.

Benefit of wonder drug DACOMITINIB over GEFATINIB in treatment of advance EGFR positive non small cell lung cancer.

Positive outcome of phase 3 data of trastuzamab with palbociclib.

First line usage of pfizer and e.merck immuno oncology product avelumab plus axitinib.

Successful phase 3 trial results of SUTENT in adjuvent setting.

Efficacy and safety of lorlatinib in ALK positive lung cancer over Crizotinib ceritinib and alectinib.